Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adaptimmune Ther ADR (ADAP)

Adaptimmune Ther ADR (ADAP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,784
  • Shares Outstanding, K 255,883
  • Annual Sales, $ 60,280 K
  • Annual Income, $ -113,870 K
  • EBIT $ -45 M
  • EBITDA $ -35 M
  • 60-Month Beta 2.18
  • Price/Sales 2.55
  • Price/Cash Flow N/A
  • Price/Book 1.92
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.22
  • Most Recent Earnings $-0.07 on 11/13/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 372.00% ( -33.04%)
  • Historical Volatility 97.60%
  • IV Percentile 90%
  • IV Rank 52.79%
  • IV High 694.05% on 02/02/24
  • IV Low 11.81% on 06/11/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 66
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 4,121
  • Open Int (30-Day) 4,066

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.14
  • Number of Estimates 4
  • High Estimate -0.05
  • Low Estimate -0.21
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5511 +9.76%
on 12/13/24
0.7400 -18.26%
on 12/02/24
-0.0598 (-9.00%)
since 11/20/24
3-Month
0.5511 +9.76%
on 12/13/24
1.0100 -40.11%
on 09/27/24
-0.3912 (-39.27%)
since 09/20/24
52-Week
0.4300 +40.67%
on 12/21/23
2.0500 -70.49%
on 03/08/24
+0.1636 (+37.07%)
since 12/20/23

Most Recent Stories

More News
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025Gavin Wood, Chief Financial Officer, will step down from the...

ADAP : 0.6049 (+0.82%)
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcomaPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December...

ADAP : 0.6049 (+0.82%)
Adaptimmune Reports Q3 2024 Financial and Business Updates

Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number...

ADAP : 0.6049 (+0.82%)
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses (21/64)Data to be presented...

ADAP : 0.6049 (+0.82%)
Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers...

ADAP : 0.6049 (+0.82%)
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with...

ADAP : 0.6049 (+0.82%)
Adaptimmune to Participate in Two Bank Conferences this September

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers...

ADAP : 0.6049 (+0.82%)
Adaptimmune Reports Q2 2024 Financial and Business Updates

Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can begin treatment journey; biomarker testing available;...

ADAP : 0.6049 (+0.82%)
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell...

ADAP : 0.6049 (+0.82%)
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysisInterim analysis data reinforces the potential...

ADAP : 0.6049 (+0.82%)

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 0.6297
2nd Resistance Point 0.6174
1st Resistance Point 0.6111
Last Price 0.6049
1st Support Level 0.5925
2nd Support Level 0.5802
3rd Support Level 0.5739

See More

52-Week High 2.0500
Fibonacci 61.8% 1.4312
Fibonacci 50% 1.2400
Fibonacci 38.2% 1.0488
Last Price 0.6049
52-Week Low 0.4300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar